DL is a 42 y/o female you diagnosis with having community acquired pneumonia during a visit to your clinic. Due to a high rate of Mycoplasma pneumonia infections in the community, you decide to prescribe azithromycin. DL is also taking lisinopril and simvastatin for essential hypertension and hyperlipidemia treatment in addition to ibuprofen as needed for headaches. Which of the following therapy modifications would be advised?

Rationale: A. Azithromycin is a macrolide that can interfere with the metabolism of statins, leading to increased systemic concentrations of simvastatin. Higher levels of simvastatin significantly elevate the risk of drug-induced myopathy and potentially fatal rhabdomyolysis. Temporarily suspending the statin during the short course of antibiotic therapy is a standard safety measure to prevent muscle toxicity. B. Continuing all medications without modification ignores a clinically significant drug-drug interaction between macrolides and HMG-CoA reductase inhibitors. While monitoring blood pressure is important for hypertension management, it does not address the primary risk of statin toxicity in this scenario. Failing to adjust therapy could lead to significant patient harm from musculoskeletal breakdown and acute renal failure. C. There is no major contraindication between azithromycin and ibuprofen that necessitates holding the analgesic for a standard course of pneumonia treatment. While ibuprofen carries a baseline risk for gastric irritation, azithromycin does not significantly potentiate this effect compared to other antibiotics. The primary concern for this specific patient remains the statin interaction rather than gastrointestinal bleeding. D. Lisinopril is an ACE inhibitor that can cause potassium retention, but azithromycin does not typically cause hyperkalemia or interact with lisinopril in a way that affects potassium levels. Holding the antihypertensive medication could result in rebound hypertension and cardiovascular stress during an active infection. The focus of therapy modification should remain on preventing the established risk of myopathy.